Sicuranza Anna, Cavalleri Alessia, Bernardi Simona
Chair of Hematology, University of Siena, Azienda Ospedaliera Universitaria, Siena, Italy.
Chair of Hematology, Department of Clinical and Experimental Sciences, University of Brescia - Unit of Blood Disease and Stem Cell Transplantation, ASST-Spedali Civili, Brescia, Italy.
Front Oncol. 2025 May 8;15:1546813. doi: 10.3389/fonc.2025.1546813. eCollection 2025.
Chronic myeloid leukemia is one of the onco-hematologic diseases in which the identification of disease markers and therapeutic advances have been particularly impactful. Despite this, significant gaps remain in our understanding of disease pathogenesis, progression, mechanisms of immune escape, and resistance to standard therapies. Recently, advances in technology and biological knowledge have drawn attention to several promising areas of research. Among these, leukemic stem cells, miRNAs, extracellular vesicles, and additional BCR::ABL1 mutations, with particular reference to the gene, have been the most extensively investigated. In this review we summarized and critically commented the main findings on these key topics over the past 5 years, evaluating their potential impact on patient management and their role in the development of new therapeutic strategies.
慢性髓性白血病是一种肿瘤血液学疾病，在这类疾病中，疾病标志物的识别和治疗进展产生了特别重大的影响。尽管如此，我们对疾病发病机制、进展、免疫逃逸机制以及对标准疗法的耐药性的理解仍存在重大差距。最近，技术和生物学知识的进步使人们关注到几个有前景的研究领域。其中，白血病干细胞、微小RNA、细胞外囊泡以及其他BCR::ABL1突变，特别是关于该基因的突变，受到了最广泛的研究。在这篇综述中，我们总结并批判性地评论了过去5年中这些关键主题的主要研究结果，评估了它们对患者管理的潜在影响及其在新治疗策略开发中的作用。
